Thiard News@F4F

@newsen.bsky.social

2 weeks ago

Keymed Biosciences Reports Impressive Annual Results for 2025 with Growth in Revenue and Product Launches Keymed Biosciences achieved remarkable financial results in 2025, marking a significant increase in revenue alongside successful product launches and clinical advances.

Keymed Biosciences Reports Impressive Annual Results for 2025 with Growth in Revenue and Product Launches #China #Beijing #Clinical_Trials #Keymed_Biosciences #Kangyueda

Thiard News@F4F

@newsen.bsky.social

2 weeks ago

Keymed Biosciences Reports Their 2025 Annual Financial Results and Future Vision Keymed Biosciences has shared its annual financial results for 2025, highlighting a significant increase in revenue and breakthroughs in its product offerings.

Keymed Biosciences Reports Their 2025 Annual Financial Results and Future Vision #China #Beijing #Keymed_Biosciences #Kangyueda #CMG901

Thiard News@F4F

@newsen.bsky.social

2 weeks ago

Keymed Biosciences Reports Significant Revenue Growth for 2025 and Updates on Business Developments Keymed Biosciences has announced strong financial results for 2025, showcasing impressive revenue growth and strategic advancements in its product pipeline.

Keymed Biosciences Reports Significant Revenue Growth for 2025 and Updates on Business Developments #China #Beijing #Keymed_Biosciences #Kangyueda #CMG901

Thiard News@F4F

@newsen.bsky.social

7 months ago

Keymed Biosciences Reports Impressive Interim Results for 2025 with Accelerated Commercialization and R&D Momentum Keymed Biosciences Inc. has reported significant interim results for 2025, showcasing strong commercialization and innovative research developments that stand out in the biotech sector.

Keymed Biosciences Reports Impressive Interim Results for 2025 with Accelerated Commercialization and R&D Momentum #China #Chengdu #Keymed_Biosciences #CMG901 #Kang_Yue_Da

Thiard News@F4F

@newsen.bsky.social

7 months ago

Keymed Biosciences Achieves Remarkable Interim Results for 2025 Keymed Biosciences Inc. reports outstanding interim results for 2025, showcasing rapid commercialization and significant R&D advancements with strong financial performance.

Keymed Biosciences Achieves Remarkable Interim Results for 2025 #China #Chengdu #Keymed_Biosciences #Stapokibart #CMG901

Thiard News@F4F

@newsen.bsky.social

7 months ago

Keymed Biosciences Showcases Strong Interim 2025 Performance with Promising R&D and Commercialization Progress Keymed Biosciences achieved impressive interim 2025 results, highlighting robust revenue from its innovative drugs and a strategic focus on research and development.

Keymed Biosciences Showcases Strong Interim 2025 Performance with Promising R&D and Commercialization Progress #China #Chengdu #AstraZeneca #Keymed_Biosciences #Stapokibart

Thiard News@F4F

@newsen.bsky.social

7 months ago

Keymed Biosciences Achieves Remarkable Interim Results in 2025, Highlighting Growth and Innovation Keymed Biosciences has reported impressive interim results for 2025, showcasing significant revenue growth and advancements in R&D to enhance its market position.

Keymed Biosciences Achieves Remarkable Interim Results in 2025, Highlighting Growth and Innovation #China #Chengdu #AstraZeneca #Keymed_Biosciences #Stapokibart

Thiard News@F4F

@newsen.bsky.social

9 months ago

Keymed Biosciences Unveils Breakthrough Findings on CM336 in New England Journal of Medicine Keymed Biosciences has announced groundbreaking results from a clinical trial of CM336, targeting autoimmune hemolytic anemia, published in NEJM.

Keymed Biosciences Unveils Breakthrough Findings on CM336 in New England Journal of Medicine #None #Chengdu #Keymed_Biosciences #CM336 #Autoimmune_Hemolytic_Anemia

Thiard News@F4F

@newsen.bsky.social

9 months ago

Keymed Biosciences Unveils Promising Clinical Trial Results of CM336 for Autoimmune Hemolytic Anemia Keymed Biosciences has announced groundbreaking outcomes from its clinical trial for CM336 treatment in autoimmune hemolytic anemia, highlighting significant patient remission.

Keymed Biosciences Unveils Promising Clinical Trial Results of CM336 for Autoimmune Hemolytic Anemia #China #Chengdu #Keymed_Biosciences #CM336 #Autoimmune_Hemolytic_Anemia

Thiard News@F4F

@newsen.bsky.social

10 months ago

Keymed Biosciences Unveils Promising Clinical Trial Results for CM336 in Treating Refractory AIHA Keymed Biosciences announced significant findings from a clinical trial of CM336, showcasing its potential as an innovative treatment for autoimmune hemolytic anemia.

Keymed Biosciences Unveils Promising Clinical Trial Results for CM336 in Treating Refractory AIHA #China #Chengdu #Keymed_Biosciences #CM336 #AIHA

Thiard News@F4F

@newsen.bsky.social

10 months ago

Keymed Biosciences Breakthrough: CM336 A New Hope for Autoimmune Hemolytic Anemia Keymed Biosciences presents positive results from a clinical trial for CM336, a bispecific antibody targeting autoimmune hemolytic anemia, published in NEJM.

Keymed Biosciences Breakthrough: CM336 A New Hope for Autoimmune Hemolytic Anemia #China #Chengdu #Keymed_Biosciences #CM336 #autoimmune_treatment

Thiard News@F4F

@newsen.bsky.social

10 months ago

Keymed Biosciences' CM336 Shows Promising Results in Latest Clinical Trials for Autoimmune Diseases Keymed Biosciences has released groundbreaking findings on CM336, a bispecific antibody treatment for autoimmune hemolytic anemia, demonstrating rapid efficacy and sustained remission.

Keymed Biosciences' CM336 Shows Promising Results in Latest Clinical Trials for Autoimmune Diseases #China #Chengdu #Autoimmune_Disease #Keymed_Biosciences #CM336

Thiard News@F4F

@newsen.bsky.social

11 months ago

Keymed Biosciences Achieves Regulatory Approval for CM518D1 to Treat Solid Tumors Keymed Biosciences has recently received IND approval for CM518D1, an ADC aimed at treating solid tumors, advancing their oncology portfolio significantly.

Keymed Biosciences Achieves Regulatory Approval for CM518D1 to Treat Solid Tumors #China #Chengdu #ADC #Keymed_Biosciences #CM518D1

Thiard News@F4F

@newsen.bsky.social

11 months ago

Keymed Biosciences Secures Research Approval for ADC Targeting Solid Tumors Keymed Biosciences recently announced the approval of CM518D1, a promising antibody-drug conjugate for solid tumor treatment, setting a milestone in oncology.

Keymed Biosciences Secures Research Approval for ADC Targeting Solid Tumors #China #Chengdu #Cancer_Treatment #Keymed_Biosciences #CM518D1

Thiard News@F4F

@newsen.bsky.social

11 months ago

Keymed Biosciences Receives IND Approval for CM518D1 to Treat Solid Tumors Keymed Biosciences has received IND approval for CM518D1, an innovative therapy targeting solid tumors, enhancing their oncology pipeline significantly.

Keymed Biosciences Receives IND Approval for CM518D1 to Treat Solid Tumors #China #Chengdu #oncology #Keymed_Biosciences #CM518D1

Thiard News@F4F

@newsen.bsky.social

11 months ago

Keymed Biosciences Celebrates IND Approval for CM518D1, a Promising Solid Tumor Treatment Keymed Biosciences has received IND approval for its novel treatment CM518D1, a groundbreaking ADC aimed at combating solid tumors in China, advancing cancer therapy.

Keymed Biosciences Celebrates IND Approval for CM518D1, a Promising Solid Tumor Treatment #China #Chengdu #antibody-drug_conjugate #Keymed_Biosciences #CM518D1

Thiard News@F4F

@newsen.bsky.social

11 months ago

Keymed Biosciences Achieves IND Approval for CM518D1 Targeting Gastrointestinal Cancers Keymed Biosciences has received IND approval for CM518D1, a novel ADC targeting gastrointestinal cancers, paving the way for clinical trials.

Keymed Biosciences Achieves IND Approval for CM518D1 Targeting Gastrointestinal Cancers #China #Chengdu #ADC #Keymed_Biosciences #CM518D1

Thiard News@F4F

@newsen.bsky.social

11 months ago

Keymed Biosciences Achieves Milestone with IND Approval for CM518D1 Treatment of Gastrointestinal Cancers Keymed Biosciences has gained IND approval for CM518D1, an innovative drug for gastrointestinal cancers, marking significant progress in cancer treatment.

Keymed Biosciences Achieves Milestone with IND Approval for CM518D1 Treatment of Gastrointestinal Cancers #China #Chengdu #Keymed_Biosciences #Gastrointestinal_Cancer #CM518D1

Thiard News@F4F

@newsen.bsky.social

1 year ago

Breakthrough Phase III Study of Stapokibart for Seasonal Allergic Rhinitis Published in Nature Medicine Keymed Biosciences announces the publication of Phase III study results on stapokibart in Nature Medicine, showcasing its efficacy for seasonal allergic rhinitis.

Breakthrough Phase III Study of Stapokibart for Seasonal Allergic Rhinitis Published in Nature Medicine #China #Chengdu #Keymed_Biosciences #Stapokibart #Nature_Medicine

Thiard News@F4F

@newsen.bsky.social

1 year ago

Keymed Biosciences Announces Breakthrough Phase-III Results for Stapokibart in Seasonal Allergic Rhinitis Keymed Biosciences has unveiled promising Phase-III study data of Stapokibart, a groundbreaking treatment for seasonal allergic rhinitis, published in Nature Medicine.

Keymed Biosciences Announces Breakthrough Phase-III Results for Stapokibart in Seasonal Allergic Rhinitis #China #Chengdu #Keymed_Biosciences #Stapokibart #IL-4Rα_Antibody

Thiard News@F4F

@newsen.bsky.social

1 year ago

Groundbreaking Phase III Study Results on Stapokibart for Seasonal Allergic Rhinitis Published in Nature Medicine The Phase III trial of Stapokibart for treating seasonal allergic rhinitis has shown promising results, as detailed in Nature Medicine.

Groundbreaking Phase III Study Results on Stapokibart for Seasonal Allergic Rhinitis Published in Nature Medicine #China #Chengdu #Keymed_Biosciences #Stapokibart #Nature_Medicine

Thiard News@F4F

@newsen.bsky.social

1 year ago

Groundbreaking Phase III Results of Stapokibart Showcase New Hope for Seasonal Allergic Rhinitis Treatment Keymed Biosciences has published Phase III results of Stapokibart, revolutionizing treatment for Seasonal Allergic Rhinitis by significantly improving patient outcomes.

Groundbreaking Phase III Results of Stapokibart Showcase New Hope for Seasonal Allergic Rhinitis Treatment #China #Chengdu #Keymed_Biosciences #Stapokibart #IL-4Rα

Thiard News@F4F

@newsen.bsky.social

1 year ago

Keymed Biosciences Reports Strong Annual Results and Promising Pipeline Developments for 2024 Keymed Biosciences has announced robust annual results for 2024, showcasing strong sales and significant advancements in their drug pipeline, including Stapokibart.

Keymed Biosciences Reports Strong Annual Results and Promising Pipeline Developments for 2024 #China #Chengdu #Keymed_Biosciences #Stapokibart #CM310

Thiard News@F4F

@newsen.bsky.social

1 year ago

Keymed Biosciences Announces Approval of Stapokibart for Seasonal Allergic Rhinitis Treatment Keymed Biosciences has secured approval for Stapokibart, a monoclonal antibody, to treat seasonal allergic rhinitis in response to patient needs.

Keymed Biosciences Announces Approval of Stapokibart for Seasonal Allergic Rhinitis Treatment #China #Chengdu #Keymed_Biosciences #Stapokibart #IL-4Rα

Thiard News@F4F

@newsen.bsky.social

1 year ago

Keymed Biosciences Receives Approval for Stapokibart in China to Treat Seasonal Allergic Rhinitis Keymed Biosciences announces the approval of Stapokibart by China's NMPA for treating seasonal allergic rhinitis, enhancing patient care.

Keymed Biosciences Receives Approval for Stapokibart in China to Treat Seasonal Allergic Rhinitis #China #Chengdu #Keymed_Biosciences #Stapokibart #NMPA

Thiard News@F4F

@newsen.bsky.social

1 year ago

Keymed Biosciences Receives Regulatory Approval for Stapokibart, a New Treatment for Allergic Rhinitis Keymed Biosciences has announced the approval of its new drug Stapokibart, which targets seasonal allergic rhinitis, enhancing patient care in China.

Keymed Biosciences Receives Regulatory Approval for Stapokibart, a New Treatment for Allergic Rhinitis #China #Chengdu #Keymed_Biosciences #Stapokibart #Allergic_Rhinitis

Thiard News@F4F

@newsen.bsky.social

1 year ago

Keymed Biosciences Gains Approval for Stapokibart, a New Drug for Seasonal Allergic Rhinitis Keymed Biosciences has received approval for Stapokibart, a drug to treat seasonal allergic rhinitis, marking a significant advancement in allergy treatment.

Keymed Biosciences Gains Approval for Stapokibart, a New Drug for Seasonal Allergic Rhinitis #China #Chengdu #Keymed_Biosciences #Stapokibart #Kangyueda

Thiard News@F4F

@newsen.bsky.social

1 year ago

Timberlyne Therapeutics Secures $180 Million for Game-Changing Monoclonal Antibody CM313 Timberlyne Therapeutics has closed a $180 million Series A financing round to promote CM313, a novel anti-CD38 monoclonal antibody designed to tackle severe autoimmune diseases.

Timberlyne Therapeutics Secures $180 Million for Game-Changing Monoclonal Antibody CM313 #United_States #San_Diego #Keymed_Biosciences #CM313 #Timberlyne

Thiard News@F4F

@newsen.bsky.social

1 year ago

Keymed Biosciences Receives Approval for Stapokibart to Treat Chronic Rhinosinusitis with Nasal Polyps Keymed Biosciences has announced that Stapokibart, a monoclonal antibody, has been approved for the treatment of chronic rhinosinusitis with nasal polyps in China, based on positive clinical trial results.

Keymed Biosciences Receives Approval for Stapokibart to Treat Chronic Rhinosinusitis with Nasal Polyps #China #Chengdu #Keymed_Biosciences #Stapokibart #Kangyueda

Thiard News@F4F

@newsen.bsky.social

1 year ago

Keymed Biosciences Receives Approval for Stapokibart to Treat Chronic Rhinosinusitis Keymed Biosciences has announced that China's NMPA approved Stapokibart for chronic rhinosinusitis with nasal polyposis, showcasing significant clinical efficacy.

Keymed Biosciences Receives Approval for Stapokibart to Treat Chronic Rhinosinusitis #China #Chengdu #Keymed_Biosciences #Stapokibart #Kangyueda